These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 23234647)

  • 1. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis.
    Burmester GR; Weinblatt ME; McInnes IB; Porter D; Barbarash O; Vatutin M; Szombati I; Esfandiari E; Sleeman MA; Kane CD; Cavet G; Wang B; Godwood A; Magrini F;
    Ann Rheum Dis; 2013 Sep; 72(9):1445-52. PubMed ID: 23234647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study.
    Takeuchi T; Tanaka Y; Close D; Godwood A; Wu CY; Saurigny D
    Mod Rheumatol; 2015 Jan; 25(1):21-30. PubMed ID: 24720551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
    Burmester GR; McInnes IB; Kremer J; Miranda P; Korkosz M; Vencovsky J; Rubbert-Roth A; Mysler E; Sleeman MA; Godwood A; Sinibaldi D; Guo X; White WI; Wang B; Wu CY; Ryan PC; Close D; Weinblatt ME;
    Ann Rheum Dis; 2017 Jun; 76(6):1020-1030. PubMed ID: 28213566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
    Weinblatt ME; McInnes IB; Kremer JM; Miranda P; Vencovsky J; Guo X; White WI; Ryan PC; Godwood A; Albulescu M; Close D; Burmester GR
    Arthritis Rheumatol; 2018 Jan; 70(1):49-59. PubMed ID: 28941039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study.
    Burmester GR; Feist E; Sleeman MA; Wang B; White B; Magrini F
    Ann Rheum Dis; 2011 Sep; 70(9):1542-9. PubMed ID: 21613310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
    Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B;
    Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
    Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
    Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate.
    Genovese MC; Lee E; Satterwhite J; Veenhuizen M; Disch D; Berclaz PY; Myers S; Sides G; Benichou O
    Ann Rheum Dis; 2013 Sep; 72(9):1453-60. PubMed ID: 23599435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
    Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O
    Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy.
    Smolen JS; Weinblatt ME; Sheng S; Zhuang Y; Hsu B
    Ann Rheum Dis; 2014 Sep; 73(9):1616-25. PubMed ID: 24699939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial.
    Taylor PC; Quattrocchi E; Mallett S; Kurrasch R; Petersen J; Chang DJ
    Ann Rheum Dis; 2011 Dec; 70(12):2119-25. PubMed ID: 21859685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.
    Yoo DH; Hrycaj P; Miranda P; Ramiterre E; Piotrowski M; Shevchuk S; Kovalenko V; Prodanovic N; Abello-Banfi M; Gutierrez-Ureña S; Morales-Olazabal L; Tee M; Jimenez R; Zamani O; Lee SJ; Kim H; Park W; Müller-Ladner U
    Ann Rheum Dis; 2013 Oct; 72(10):1613-20. PubMed ID: 23687260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
    Emery P; Fleischmann RM; Moreland LW; Hsia EC; Strusberg I; Durez P; Nash P; Amante EJ; Churchill M; Park W; Pons-Estel BA; Doyle MK; Visvanathan S; Xu W; Rahman MU
    Arthritis Rheum; 2009 Aug; 60(8):2272-83. PubMed ID: 19644849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
    Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study.
    Genovese MC; Van den Bosch F; Roberson SA; Bojin S; Biagini IM; Ryan P; Sloan-Lancaster J
    Arthritis Rheum; 2010 Apr; 62(4):929-39. PubMed ID: 20131262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.
    Weinblatt ME; Mease P; Mysler E; Takeuchi T; Drescher E; Berman A; Xing J; Zilberstein M; Banerjee S; Emery P
    Arthritis Rheumatol; 2015 Oct; 67(10):2591-600. PubMed ID: 26138593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.
    Burmester GR; McInnes IB; Kremer JM; Miranda P; Vencovský J; Godwood A; Albulescu M; Michaels MA; Guo X; Close D; Weinblatt M
    Arthritis Rheumatol; 2018 May; 70(5):679-689. PubMed ID: 29361199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.